留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

长效GLP-1受体激动剂的临床研究进展

谢静 杨刚毅

谢静, 杨刚毅. 长效GLP-1受体激动剂的临床研究进展[J]. 分子影像学杂志, 2016, 39(4): 428-431. doi: 10.3969/j.issn.1674-4500.2016.04.24
引用本文: 谢静, 杨刚毅. 长效GLP-1受体激动剂的临床研究进展[J]. 分子影像学杂志, 2016, 39(4): 428-431. doi: 10.3969/j.issn.1674-4500.2016.04.24
Jing XIE, Gangyi YANG. Advance in study of long-acting glucagon-like peptide-1 receptor agonist[J]. Journal of Molecular Imaging, 2016, 39(4): 428-431. doi: 10.3969/j.issn.1674-4500.2016.04.24
Citation: Jing XIE, Gangyi YANG. Advance in study of long-acting glucagon-like peptide-1 receptor agonist[J]. Journal of Molecular Imaging, 2016, 39(4): 428-431. doi: 10.3969/j.issn.1674-4500.2016.04.24

长效GLP-1受体激动剂的临床研究进展

doi: 10.3969/j.issn.1674-4500.2016.04.24
基金项目: 

教育部博士点基金 20125503110003

详细信息
    作者简介:

    谢静,在读硕士研究生,E-mail: 279878409@qq.com

    通讯作者:

    杨刚毅,博士,教授,博士生导师,E-mail: gangyiyang@163.com

Advance in study of long-acting glucagon-like peptide-1 receptor agonist

  • 摘要: 胰高血糖素样肽1受体激动剂(GLP-1RA)是一种新型降糖药物,长效GLP-1RA通过改造结构延长其半衰期,每周仅需注射1次,使用便捷,正受到广泛关注,目前国内尚未上市,国外已上市的有艾塞纳肽长效注射液、阿必鲁肽及杜拉糖肽,各系列研究均表明无论在单药治疗还是替代传统基础胰岛素及餐时胰岛素治疗方面均能有效降低HbA1c、改善体质量及低血糖发生率低等优势,且严重不良反应事件发生率低,其中胃肠道反应及局部注射反应为最主要的不良反应,也是长效GLP-1RA在未来研发中需要注意的问题。

     

  • [1] 宁光.肥胖与2型糖尿病的流行趋势及其深远影响[J].内科理论与实践ISTIC, 2012, 7(3): 149-51. http://www.cnki.com.cn/Article/CJFDTOTAL-NKLL201203002.htm
    [2] Xu Y, Wang LM, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-58. doi: 10.1001/jama.2013.168118
    [3] Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes-realistic estimates for the year 2000[J]. Diabetes Care, 2005, 28(9): 2130-5. doi: 10.2337/diacare.28.9.2130
    [4] 陈玉, 周玲, 徐耀初, 等. 2型糖尿病与遗传和环境因素相互关系的研究[J].中华预防医学杂志, 2002, 36(3): 191-4. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYF200203018.htm
    [5] 邓吉容, 唐兰, 李革, 等.肥胖是发生糖尿病的危险因素[J].重庆医学, 2006, 35(10): 886-9. http://www.cnki.com.cn/Article/CJFDTOTAL-CQYX200610008.htm
    [6] 郭立新. 2型糖尿病传统降糖治疗的问题与挑战[J].药品评价, 2014, 11(15): 27-31. http://www.cnki.com.cn/Article/CJFDTOTAL-YPPJ201415007.htm
    [7] Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-39. doi: 10.1152/physrev.00034.2006
    [8] Deng WQ, Qiu S, Yang GY, et al. Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives[J]. Ther Clin Risk Manag, 2015, 11(3): 1153-62. https://www.ncbi.nlm.nih.gov/pubmed/26309403
    [9] Kim W1. Egan JM.the role of incretions in glucose homeostasis and diabetes treatment[J]. Pharmacol Rev, 2008, 60(4): 470-512. doi: 10.1124/pr.108.000604
    [10] Bydureon package insert. Available at http://www.azpicentral.com/bydureon/pi_bydureon.pdfpage=1 [Last accessed:Dec 28th, 2015].
    [11] Tanzeum package insert.Available at https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF [Last accessed:Dec 28th, 2015].
    [12] Trulicity package insert. Available at http://pi.lilly.com/us/trulicityuspi.pdf [Last accessed:Dec 28th, 2015].
    [13] Wysham CH, Macconell LA, Maggs DG, et al. Five-Year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial[J]. Mayo Clinic Proceedings, 2015, 90(3): 356-65. doi: 10.1016/j.mayocp.2015.01.008
    [14] Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide(HARMONY 2):52 week primary endpoint results from a randomised, placebocontrolled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise[J]. Diabetologia, 2016, 59(2): 266-74. doi: 10.1007/s00125-015-3795-1
    [15] Umpierrez G, Tofé PS, Pérez MF, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)[J]. Diabetes Care, 2014, 37 (8): 2168-76. doi: 10.2337/dc13-2759
    [16] Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial[J]. The Lancet Diabetes & Endocrinology, 2014, 2(6): 464-73. http://www.ncbi.nlm.nih.gov/pubmed/24731672
    [17] Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutideversus insulin glargine in patients with type 2 diabetes on metformin and glimepiride(AWARD-2)[J]. Diabetes Care, 2015, 38(12): 2241-9. doi: 10.2337/dc14-1625
    [18] Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study[J]. Lancet, 2015, 385 (9982): 2057-66. doi: 10.1016/S0140-6736(15)60936-9
    [19] Weissman PN, Carr MC, Ye JE, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea[J]. Diabetologia, 2014, 57(12): 2475-84. doi: 10.1007/s00125-014-3360-3
    [20] Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus Thrice-Daily prandial insulin lispro[J]. Diabetes Care, 2014, 37(8): 2317-25. doi: 10.2337/dc14-0001
  • 加载中
计量
  • 文章访问数:  1047
  • HTML全文浏览量:  308
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-02-07
  • 刊出日期:  2016-04-01

目录

    /

    返回文章
    返回